STORM Therapeutics names Marguerite Hutchinson as CBO

UK clinical-stage biotech STORM Therapeutics, which is targeting RNA modifying enzymes (RMEs) for oncology and other diseases, has appointed Marguerite Hutchinson as its chief business officer.

Ms Hutchinson joins STORM from Tatara Therapeutics, where she was chief executive of the UCSF spin-out which she set up and raised seed financing.

Ms Hutchinson has over 10 years’ extensive experience in leading licensing agreements and collaborations with large, high profile healthcare companies as well as experience in legal and strategic operations. She was previously the chief operating officer and general counsel of Plexxikon, a member of the Daiichi Sankyo (TYO: 4568) group, establishing and managing collaborations with Roche, Merck, AstraZeneca, Array and Cancer Research UK.